Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002227 · ClinicalTrials.gov registry record · Phase 2
A Study of Efavirenz in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs
A Phase 2 study, sponsored by Dupont Merck.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT00002227: Completed Phase 2 study, sponsored by Dupont Merck.
NCT00002227 is a Phase 2 study that has completed, run by Dupont Merck. The registered enrollment target is 60 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (55% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002227, a Phase 2 study, has completed, sponsored by Dupont Merck.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
The purpose of this study is to see if it is safe and effective to give efavirenz plus stavudine plus lamivudine to patients who have never taken anti-HIV drugs.
Interventions
- DRUG Lamivudine
- DRUG Efavirenz
- DRUG Stavudine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Phase | Phase 2 |
What the finished NCT00002227 record still lists
NCT00002227 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (55% lower).
The record links to 0 conditions, and to 3 interventions - of which Lamivudine is the first listed.
NCT00002227 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002227 about?
NCT00002227 is a clinical study titled "A Study of Efavirenz in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs". The purpose of this study is to see if it is safe and effective to give efavirenz plus stavudine plus lamivudine to patients who have never taken anti-HIV drugs.
What is the current status of trial NCT00002227?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants.
What interventions are being tested in trial NCT00002227?
The interventions under investigation include: Lamivudine (DRUG), Efavirenz (DRUG), Stavudine (DRUG).
Who is sponsoring clinical trial NCT00002227?
This trial is sponsored by Dupont Merck, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00002227's enrollment target sits among peer trials
60 1027th of 2000 higher than 868 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors